Show Notes
Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 28, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.
This time—Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Ziihera in gastroesophageal cancer; and Teva and Viatris pivoting from generics to novel drugs.
This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn.
Contact us on [email protected].
More from Scrip Podcasts
Ahead of the awards presentation on Dec 2, the Scrip Awards podcast speaks to Mathai Mammen, CEO of Parabilis, one of the shortlisted companies for Biotech of The Year.
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月16日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。
Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things.
Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things.
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月9日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。本周内容包括：中国带来的竞争威胁；第三季度并购活动降温；新型肺炎球菌疫苗竞争者；西班牙生物技术公司的战略；以及盐野义制药20亿美元的收购案。